Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to...
-
2026 State of Validation study intensifying workload demands alongside advancements in digital validation and AI adoption.
-
Austin, TX, USA, April 29, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Cell Culture Media Bags Market Size, Trends and Insights By Capacity...
-
Orelabrutinib is the first BTKi to demonstrate significant efficacy in a Phase II clinical trial for SLE, which affects around 8 million people worldwide.
-
One of Europe’s largest CDMOs selects Kneat to power their digital validation transformation, starting with their equipment validation processes.
-
InnoCare remained profitable in the first quarter of 2026, with net profit increasing by 607.7% YoY to RMB 102.4 million.
-
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived...
-
Kneat will release its financial results for the quarter ended March 31, 2026, after TSX market close on May 13, 2026.
-
Bolstered leadership team positions Paratus to accelerate PS-1001 toward the clinic and build a pipeline of differentiated medicines.
-
PharmAla files Q2 quarterly financials with increased customer deposits.